Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of F182112 in combination with different dosing regimens for relapsed or refractory multiple myeloma
CTR20250778Phase 2Active
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- May 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of F182112 in multiple myeloma (MM), sponsored by Shandong New Era Pharmaceutical. Started May 2025; status: active.
02
Drugs
F182112
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20250778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250778.